2013年乳癌重大進展回顧 (美國臨床腫瘤醫學會ASCO)

1. Longer-term tamoxifen therapy substantially reduces risks of breast cancer recurrence and death.
術後長期使用Tamoxifien作為輔助性賀爾蒙治療大幅降低早期荷爾蒙陽性乳癌病患復發以及死亡率

(由兩個大型第三期臨床試驗ATLAS & aTTom結果得知, 於早期荷爾蒙陽性乳癌, 使用長期10年tamoxifen較使用5年tamoxifen, 可降低乳癌復發率以及死亡率, 尤其對於年輕停經前病患可考慮使用)

2. Weekly adjuvant paclitaxel therapy has comparable efficacy but fewer side effects than the biweekly regimen.
術後使用每週輔助性paclitaxel太平洋紫杉醇化學治療, 相較兩週一次的方式, 療效一樣, 但副作用較少

3. FDA approves ado-trastuzumab emtansine for patients with human epidermal growth factor receptor 2–positive, metastatic breast cancer.
美國 FDA核准 ado-trastuzumab emtansine於HER-2陽性之轉移性乳癌病患

參考資料

1. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
2. Gray RG, Rea D, Handley K, et al:  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. aTTom presented at ASCO 2013.  J Clin Oncol 31, 2013 (suppl; abstr 5)
3. Budd GT, Barlow WE, Moore HCF, et al:  S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31, 2013 (suppl; abstr CRA1008)
4. US Food and Drug Administration: FDA approves new treatment for late-stage breast cancer.
5. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012 

備註: 上述僅提供參考, 建議病患仍須與自己的主治醫師討論治療方式